Clinical Features of Chinese Patients with Thyroid Eye Disease: A Multicenter Retrospective Study.

Thyroid eye disease (TED) is a debilitating autoimmune disorder linked to thyroid dysfunction. There is limited knowledge of TED in Asian populations. This multicenter study characterizes the clinical features and treatment response of TED in a large Chinese cohort. A retrospective multicenter study included 4157 patients with TED from nine Chinese hospitals from February 2016 to July 2023. Disease severity and activity were evaluated according to the European Group on Graves' Orbitopathy standards. We examined associations of variables including sex, age, smoking status, I treatment, consultation department, and geographical region with clinical outcomes. Logistic regression and nomogram models were developed to examine associations with sight-threatening TED and, in a subgroup analysis ( = 126), patients' responsiveness to intravenous glucocorticoid (IVGC) therapy. We included 4157 patients with mean age and standard deviation (SD) 45.96 ± 16.44 years. Of these, 63.6% ( = 2644) were females. Over half (55.6%, = 2310) of participants were in the inactive phase, with a mean clinical activity score of 2.19 ± 1.61 (SD) for all patients. TED severity was categorized as mild (9.3%, = 385), moderate-to-severe (82.5%, = 3428), and sight-threatening (8.2%, = 344). The average degree of exophthalmos was 20.04 ± 5.27 mm, and 48.8% ( = 2029) of patients had diplopia. Patients treated with I had higher disease activity (47.5%, = 468, vs. 43.5%, = 1379, < 0.05). Coastal region patients exhibited more severe TED (sight-threatening cases: 10.1%, = 195, vs. 7.2%, = 147) and higher diplopia scores (1.00 ± 1.10 vs. 0.86 ± 1.09, < 0.001) than inland counterparts. TED severity was also greater in patients treated in Ophthalmology departments (mild cases: 6.0%, = 213; moderate-to-severe cases: 85.6%, = 3055) compared with Endocrinology departments (mild cases: 29.3%, = 172; moderate-to-severe cases: 63.5%, = 373). Nomograms had an area under the receiver operating curve of 0.742 (confidence interval [CI] 0.716-0.768) for sight-threatening TED and 0.759 (CI 0.674-0.843) for IVGC therapy responsiveness. We characterized the clinical features and treatment response of TED in a large Chinese cohort. These findings offer valuable insights informing TED risk stratification in Asian patients and forming a foundation for future prospective studies.